First-in-class therapy targets 'undruggable' protein in hard-to-treat blood cancers
Researchers at MD Anderson Cancer Center have identified a new experimental drug, GT19630, that targets the MYC protein in blood cancers. By disrupting the relationship between MYC and GSPT1, the therapy shows potential for treating previously 'undruggable' and treatment-resistant cancers.
Why it matters
MYC is a driver in 70% of human cancers, and this discovery could lead to a breakthrough in treating aggressive, hard-to-cure malignancies.
by Stefanie Peeler, University of Texas MD Anderson Cancer Center
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Credit: Unsplash/CC0 Public Domain A first-in-class therapy to target MYC, one of the most sought-after and difficult targets in cancer biology, showed promise in hard-to-treat blood cancers, according to a new preclinical study from The University of Texas MD Anderson Cancer Center published in Blood .
Researchers led by Michael Andreeff, M.D., Ph.D., professor, and Yuki Nishida, M.D., Ph.D., assistant professor, both of Leukemia, found that the experimental drug GT19630 interrupts a newly discovered cycle between MYC and GSPT1, resulting in strong anticancer activity in preclinical models of leukemia, lymphoma and multiple myeloma, including treatment-resistant and TP53-mutated disease.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in